Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
November 18, 2022 08:00 ET
|
Candel Therapeutics
CAN-3110 designed to limit replication and promote anti-tumor response to tumor cells while protecting healthy tissueNo dose-limiting toxicities observed in 41 patients with recurrent high-grade...
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma
November 11, 2022 12:00 ET
|
Candel Therapeutics
Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standard of careSystemic immune activation was observed...
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 10, 2022 08:00 ET
|
Candel Therapeutics
Discovery collaboration underway with Center for Cellular Immunotherapies Lab at University of Pennsylvania to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy Candidates in...
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
November 07, 2022 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced new...
Candel Therapeutics Upcoming Investor Conference Participation for November
November 01, 2022 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that...
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
October 26, 2022 08:00 ET
|
Candel Therapeutics
Goal of evaluating combination of novel viral immunotherapies with aim to potentiate CAR-T cell therapies in solid tumors Employs Candel’s enLIGHTEN™ Discovery Platform Both parties retain rights in...
Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma
September 15, 2022 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (Candel or the Company), a late clinical stage biopharmaceutical company developing novel oncolytic viral...
Candel Therapeutics Announces Two Executive Leadership Appointments
September 07, 2022 08:00 ET
|
Candel Therapeutics
Jason A. Amello joins Candel as Chief Financial OfficerGarrett Nichols, MD, MS, joins Candel as Chief Medical Officer NEEDHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc....
Candel Therapeutics Upcoming Investor Conference Participation
September 06, 2022 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
August 05, 2022 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight...